ArticleFrontiers in immunology2026
Serum protein biomarkers for polymyalgia rheumatica: a case-control study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Polymyalgia rheumatica (PMR), a chronic inflammatory disease that affects older people, is characterized by musculoskeletal pain in the shoulder, neck, and pelvic girdle. It can be challenging to discriminate PMR from older age onset rheumatoid arthritis (RA). Systematic investigations of serum proteins have been conducted to identify new biomarkers. However, few proteomic analyses have been conducted for PMR. We analyzed serum protein profiles to identify biomarkers of PMR in the comparison between PMR patients before corticosteroid treatment [PMR Tx(-)] and healthy controls (HCs). Methods: Systematic proteome analyses of serum samples from 16 PMR Tx(-) and 18 HCs were performed and candidate proteins were selected with statistical/cluster and outlier analyses. Validation of the results was performed by the multiplex bead-based immunoassay of 10 candidate proteins in serum from 16 PMR Tx(-), 30 PMR after corticosteroid treatment [PMR Tx(+)], 26 RA, and 16 HCs. Results: C-C motif chemokine ligand (CCL)7, C-X-C motif chemokine ligand (CXCL)9, interleukin (IL)-6, matrix metalloproteinase (MMP)-8, interferon (IFN)-alpha, and MMP-3 levels were increased in PMR Tx(-) compared with HC. Area under the curve values of receiver operating characteristic curves of CXCL9, IL-6, and IL-1 receptor antagonist were 0.94, 0.97, and 0.94, respectively. Conclusions: Serum biomarker profiles could represent diagnostic biomarkers for PMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.